Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults

Abstract

This randomized, double-blind, noninferiority trial was designed to demonstrate that pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 mg) was at least as effective clinically as amoxicillin-clavulanate 875/125 mg, both given twice daily for 7 days, in the treatment of community-acquired pneumonia in adults. In total, 633 clinically and radiologically confirmed community-acquired pneumonia patients (intent-to-treat population) were randomized to receive either oral amoxicillin-clavulanate 2,000/125 mg (n ‫؍‬ 322) or oral amoxicillin-clavulanate 875/125 mg (n ‫؍‬ 311). At screening, 160 of 633 (25.3%) patients had at least one typical pathogen isolated from expectorated or invasive sputum samples or blood culture (bacteriology intent-to-treat population). Streptococcus pneumoniae (

Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia

“…Moreover, search for Streptococcus pneumoniae antigen in urine was not routinely done. However, using representative respiratory secretions and blood cultures the rate of documented bacterial CAPs in our study was very similar to the one in different recent studies [38] or [39]. …”

Management of Nonsevere Pneumonia in Military Trainees with the Urinary Antigen Test for Streptococcus pneumoniae: An Innovative Approach to Targeted Therapy

“…Thus, it may be claimed that our targeted approach may not be possible in geographic areas where highlevel penicillin resistance exists for S. pneumoniae. We point out, however, that numerous studies have documented that penicillin resistance, as defined by NCCLS criteria, has little impact on clinical outcome, even when discordant antibiotic therapy is administered [34][35][36][37].…”

Controversies in the Treatment of Pneumococcal Community-Acquired Pneumonia

“…While a number of studies suggest limited or no impact of β-lactam resistance [6,[11][12][13][14][15], there are a number of studies that purport to show an impact of antibiotic, and in particular penicillin resistance, on the outcome of pneumococcal infections treated with standard β-lactam antibiotics [15][16][17][18][19]. This was also reported in a recent systematic review and meta-analysis [20].…”